CLINICAL_TRIALS
trial_result
· 2025-05-23
Clinical Trial Update: Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma [Phase 2]
Summary
Phase 2 trial evaluating the efficacy and safety of bb2121 in relapsed and refractory multiple myeloma has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2025-05-23